381 Article(s)Download |
||||||
PMID | Title | Pub. Year | #Total Relationships |
|||
351 | 11694787 | Interaction between Herceptin and taxanes. | 2001 | 1 | ||
352 | 11706391 | Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. | 2001 Oct | 11 | ||
353 | 11759824 | Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. | 2001 Sep | 1 | ||
354 | 11770175 | [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer]. | 2001 Nov 18 | 2 | ||
355 | 11787463 | Trastuzumab: new preparation. May help some patients with breast cancer, but too many unknowns. | 2001 Aug | 1 | ||
356 | 11822753 | Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. | 2001 Nov | 3 | ||
357 | 11989523 | Trials of new combinations of Herceptin in metastatic breast cancer. | 2001 Dec | 2 | ||
358 | 10601557 | Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. | 2000 Jan | 2 | ||
359 | 10623878 | Role of HER2 gene overexpression in breast carcinoma. | 2000 Feb | 1 | ||
360 | 10656456 | E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. | 2000 Jan | 21 | ||
361 | 10699953 | Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. | 2000 Mar 1 | 2 | ||
362 | 10749863 | Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. | 2000 Jun 9 | 2 | ||
363 | 10781891 | Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. | 2000 Apr 3 | 5 | ||
364 | 10873087 | Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. | 2000 Jun | 1 | ||
365 | 10878580 | Role of erbB2 in breast cancer chemosensitivity. | 2000 Jul | 1 | ||
366 | 10898354 | Developments in chemotherapy of breast cancer. | 2000 Jun 15 | 2 | ||
367 | 11236027 | Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. | 2000 Dec | 1 | ||
368 | 11899388 | Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. | 2000 Apr | 2 | ||
369 | 11970748 | Rationale and use of epirubicin-based therapy in the adjuvant setting. | 2000 Sep | 2 | ||
370 | 12845342 | Transcriptional targeting of the HER-2/neu oncogene. | 2000 Dec | 1 | ||
371 | 10211534 | Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. | 1999 Feb | 1 | ||
372 | 10399623 | c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. | 1999 Apr-Jun | 4 | ||
373 | 10534697 | Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. | 1999 Nov | 2 | ||
374 | 9572489 | Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. | 1998 Apr 23 | 10 | ||
375 | 9661897 | Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. | 1998 Jul 1 | 6 | ||
376 | 9844631 | Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. | 1998 Nov | 6 | ||
377 | 10388129 | Paclitaxel in Breast Cancer. | 1998 | 1 | ||
378 | 9285690 | Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. | 1997 Aug 18 | 10 | ||
379 | 9337349 | Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1) | 1997 Oct 15 | 1 | ||
380 | 9374103 | Future directions of paclitaxel-based therapy of breast cancer. | 1997 Oct | 5 | ||
381 | 8808711 | Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. | 1996 Sep 19 | 5 |